(EMAILWIRE.COM, January 31, 2019 ) The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing.

The report segments the global specimen validity testing market by product and service, type, end user, and region.

The specimen validity testing market is broadly segmented into products and services. The services segment is expected to register the highest growth rate during the forecast period. The high growth in this segment is attributed to the implementation of workplace drug testing in several countries, increase in the number of drug screening tests, and growing number of drug screening laboratories across the globe.

Based on product, the specimen validity testing market is categorized into reagents, calibrators, & controls; assay kits; and disposables. In 2018, the reagents, calibrators, and controls segment is expected to account for the largest share of the market, owing to the repeated purchase of these products.

Request sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=147024121

The global specimen validity testing market by type is segmented into laboratory testing and rapid/POC testing. In 2018, the laboratory testing segment is expected to account for the largest share of the market. However, the rapid/POC testing segment is expected to register the highest growth during the forecast period. The high growth of the rapid/POC testing segment can be attributed benefits such as instant results, ability to detect multiple drugs at once, and the recurrent & repetitive usage of rapid/POC drug testing products.

Based on end user, the specimen validity testing market is segmented into workplaces, drug screening laboratories, criminal justice and law enforcement agencies, pain management centers, drug rehabilitation centers, and other end users. In 2018, the workplaces segment is expected to account for the largest share of the market. The growth in this segment can be attributed to the increasing incidence of substance abuse in the workplace and the growing number of organizations that have made regular drug screening mandatory.

The market is dominated by North America, followed by Europe. The dominance of the North American market is attributed to factors such as the growing consumption of illicit drugs, the presence of stringent laws mandating drug screening, availability of government funding (to help curb drug abuse), and the presence of key players in the region.

While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests.

The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher (US), Sciteck (US), American Bio Medica Corporation (ABMC), Alere (US), Express Diagnostics (US), and Premier Biotech. While, LabCorp (US), Quest Diagnostics (US), Alere Toxicology (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.

Know More: https://www.marketsandmarkets.com/Market-Reports/specimen-validity-testing-market-147024121.html